Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 14/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012755 | 0.81 | KMT2A (0.56) | FBP1ALDH1A1TSHRHTTSMN1; SMN2 | |
| SCHEMBL2007912 | 0.81 | FBP1 (0.53) | FBP1CYP2C9ALDH1A1LMNAALB | |
| SCHEMBL2008042 | 0.81 | FBP1 (0.53) | FBP1CYP2C9ALDH1A1LMNAALB | |
| SCHEMBL2008078 | 0.81 | SMN1; SMN2 (0.55) | FBP1HTTMAPK1SMN1; SMN2 | |
| SCHEMBL2007213 | 0.80 | FBP1 (0.47) | FBP1CYP2C9ALDH1A1LMNAALB | |
| SCHEMBL2008704 | 0.78 | FBP1 (0.48) | FBP1CYP2C9ALDH1A1LMNAALB | |
| SCHEMBL2007670 | 0.77 | LMNA (0.56) | FBP1CYP2C9ALDH1A1LMNAALB | |
| SCHEMBL2005603 | 0.74 | CYP2D6 (0.54) | FBP1CYP2C9ALDH1A1TSHR | |
| SCHEMBL2007978 | 0.71 | HTT (0.53) | FBP1CYP2C9ALDH1A1LMNAALB | |
| SCHEMBL27755923 | 0.70 | MEN1 (0.41) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081889-B1 | SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | claimed |
| US-7964633-B2 | such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2081889-B1 | SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2081889-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20080085928-A1 | Sulfonamide derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-10 | — | — | US | disclosed |
| WO-2008037628-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085928-A1 | Sulfonamide derivatives | SULT2A1, SULT1A1, SULT1E1 | FBP1 2209/4885CYP2C9 49/4885ALDH1A1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.